STOCK TITAN

[8-K] Cycurion, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Cycurion, Inc. (CYCU) reported a Nasdaq delisting determination and filed an appeal. The company received notice on October 14, 2025 that its common stock is subject to delisting from the Nasdaq Global Market after failing to regain compliance with the $1.00 bid price rule. Cycurion submitted an appeal on October 20, 2025, which stays any suspension and Form 25-NSE filing pending a panel decision, with hearings typically set 30–45 days after the request.

To address the bid-price deficiency, the board approved a 30:1 reverse stock split expected to take effect on October 27, 2025, following prior stockholder approval of a reverse-split range. The company also announced five new contracts totaling approximately $1 million, expected to add $75,000 in monthly recurring revenue. If the appeal is unsuccessful, the shares may move to the over-the-counter market, which the company notes is a more limited and less liquid trading venue and could pressure the stock price.

Cycurion, Inc. (CYCU) ha comunicato una decisione di delisting da Nasdaq e ha presentato un ricorso. L'azienda ha ricevuto la notifica il 14 ottobre 2025 che il suo titolo comune è soggetto a delisting dal Nasdaq Global Market dopo non aver rispettato la regola del prezzo di offerta di $1,00. Cycurion ha presentato ricorso il 20 ottobre 2025, che sospende qualsiasi sospensione e la presentazione del Form 25-NSE in attesa della decisione di un pannello, con le udienze tipicamente fissate 30–45 giorni dopo la richiesta.

Per correggere la carenza nel prezzo di offerta, il consiglio di amministrazione ha approvato un reverse stock split di 30:1 previsto per l'entrata in vigore il 27 ottobre 2025, a seguito dell'approvazione precedente da parte degli azionisti di un intervallo di divisione inversa. L'azienda ha anche annunciato cinque nuovi contratti per un totale di circa 1 milione di dollari, che ci si aspetta aggiungano 75.000 dollari di entrate ricorrenti mensili. Se il ricorso non avrà esito positivo, le azioni potrebbero passare al mercato over-the-counter, che l'azienda indica come un recinto di negoziazione più limitato e meno liquido e potrebbe esercitare pressioni sul prezzo delle azioni.

Cycurion, Inc. (CYCU) informó de una determinación de exclusión de Nasdaq y presentó una apelación. La compañía recibió aviso el 14 de octubre de 2025 de que su acción ordinaria está sujeta a la exclusión del Nasdaq Global Market tras no haber logrado volver al cumplimiento con la regla de precio de oferta de $1,00. Cycurion presentó una apelación el 20 de octubre de 2025, que suspende cualquier suspensión y la presentación del Form 25-NSE hasta la decisión de un panel, con audiencias típicamente programadas 30–45 días después de la solicitud.

Para abordar la deficiencia del precio de oferta, la junta aprobó un split inverso de 30:1 que se espera entre en vigor el 27 de octubre de 2025, tras la aprobación previa de los accionistas de un rango de división inversa. La empresa también anunció cinco nuevos contratos por un total de aproximadamente $1 millón, que se espera que agreguen $75,000 en ingresos recurrentes mensuales. Si el recurso no tiene éxito, las acciones podrían pasar al mercado de comercio extrabursátil, que la empresa señala como un recinto de negociación más limitado y menos líquido y podría presionar el precio de las acciones.

Cycurion, Inc. (CYCU)는 나스닥 상장 말소 결정에 따른 조치를 발표했고 항소를 제기했다. 회사는 2025년 10월 14일에 보통주가 $1.00의 호가가 기준을 충족하지 못해 나스닥 글로벌 마켓에서의 상장폐지 대상임을 통지받았다. Cycurion은 2025년 10월 20일에 항소를 제기했으며, 이는 패널 결정까지 정지 및 Form 25-NSE 제출을 보류하며, 청문회는 일반적으로 요청 후 30~45일 내에 설정된다.

호가 요건을 해결하기 위해 이사회는 30:1의 주식 분할을 승인했고, 이는 2025년 10월 27일에 효력을 발휘할 예정이며, 역분할 범위에 대한 주주 승인을 받았다. 회사는 또한 약 100만 달러의 다섯 건의 신규 계약를 발표했고, 월 7만5천 달러의 재발생 수익을 추가할 것으로 예상된다. 항소가 성공하지 못하면 주식은 장외시장으로 이동할 수 있으며, 이는 거래 용량이 더 제한적이고 유동성이 낮은 거래 장소로 간주되며 주가에 압력을 가할 수 있다.

Cycurion, Inc. (CYCU) a annoncé une décision de radiation de Nasdaq et a déposé un recours. La société a reçu le 14 octobre 2025 une notification selon laquelle son action ordinaire est sujette à une radiation du Nasdaq Global Market après n'avoir pas retrouvé le respect de la règle de prix d’offre de 1,00 $. Cycurion a déposé un recours le 20 octobre 2025, qui suspend toute suspension et le dépôt du formulaire 25-NSE en attendant la décision d’un panel, les audiences étant généralement prévues 30 à 45 jours après la demande.

Pour remédier à la déficience du prix d’offre, le conseil d’administration a approuvé un fractionnement inverse de 30:1 qui devrait prendre effet le 27 octobre 2025, après l’approbation préalable par les actionnaires d’une plage de fractionnement inverse. La société a également annoncé cinq nouveaux contrats pour un montant total d’environ 1 million de dollars, qui devraient ajouter 75 000 dollars de revenus récurrents mensuels. Si l’appel échoue, les actions pourraient être transférées au marché des valeurs hors cote (over-the-counter), que la société décrit comme un lieu de négociation plus limité et moins liquide et qui pourrait exercer une pression sur le cours.

Cycurion, Inc. (CYCU) meldete eine Nasdaq-Delisting-Bewertung und legte Berufung ein. Das Unternehmen erhielt am 14. Oktober 2025 die Mitteilung, dass seine Stammaktie aufgrund des Nichteinhaltens der $1,00-Bid-Price-Regel vom Nasdaq Global Market delisted wird. Cycurion legte am 20. Oktober 2025 Berufung ein, wodurch jegliche Suspendierung und die Einreichung von Form 25-NSE bis zur Entscheidung eines Panels ausgesetzt werden, mit hearings typischerweise 30–45 Tage nach der Anfrage.

Um die Bid-Price-Defizit zu beheben, hat der Vorstand eine 30:1 reverse stock split genehmigt, der voraussichtlich am 27. Oktober 2025 in Kraft tritt, nach zuvor von den Aktionären genehmigtem Bereich des Reverse-Splits. Das Unternehmen kündigte außerdem fünf neue Verträge im Gesamtwert von ca. 1 Million Dollar an, von denen erwartet wird, dass sie 75.000 Dollar an monatlich wiederkehrenden Einnahmen hinzufügen. Sollte die Berufung scheitern, könnten die Aktien in den OTC-Markt übergehen, den das Unternehmen als einen begrenzteren und weniger liquiden Handelsplatz bezeichnet und der den Aktienkurs unter Druck setzen könnte.

سيكيرورين، Inc. (CYCU) أبلغت عن قرار إزالة من ناسداك وقدمت استئنافاً. تلقّت الشركة إخطاراً في 14 أكتوبر 2025 بأن أسهمها العادية تُعرض للإزالة من Nasdaq Global Market بعد فشلها في استعادة الامتثال لقاعدة سعر العرض البالغ 1.00 دولار. قدّمت سيكيرورين استئنافاً في 20 أكتوبر 2025، مما يوقف أي تعليق وتقدّم Form 25-NSE حتى قرار اللجنة، مع جلسات استماع عادة ما تكون خلال 30–45 يوماً من الطلب.

ولمعالجة نقص سعر العرض، صوت المجلس بالموافقة على تجزيء عكسي 30:1 من المتوقع أن يدخل حيز التنفيذ في 27 أكتوبر 2025، عقب موافقة المساهمين السابقة على نطاق التجزئة العكسي. كما أعلنت الشركة خمسة عقود جديدة بإجمالي نحو 1 مليون دولار، متوقّع أن تُضيف 75,000 دولار شهرياً في الإيرادات المتكررة. إذا فشلت الاستئناف، فقد تنتقل الأسهم إلى السوق خارج البورصة OTC، وهو سوق أكثر محدودية وأقل سيولة وقد يضغط على سعر السهم.

Cycurion, Inc. (CYCU) 报告了纳斯达克退市决定并提出上诉。 公司在 2025 年 10 月 14 日收到通知,普通股因未能重新符合 $1.00 的出价价格规则而可能被纳斯达克全球市场退市。Cycurion 于 2025 年 10 月 20 日提交上诉,该上诉在小组决定前暂停任何暂停和 Form 25-NSE 的提交,听证会通常在请求后 30–45 天举行。

为解决出价不足的问题,董事会批准了一个 30:1 的股票分拆,预计于 2025 年 10 月 27 日生效,此前股东已批准了分拆区间。公司还宣布 五项新合同,总额约 100 万美元,预计将新增 每月 75,000 美元的经常性收入。如果上诉不成功,股票可能转至场外交易市场 OTC,该市场交易量较小、流动性较低,可能对股价造成压力。

Positive
  • None.
Negative
  • Nasdaq delisting proceedings initiated due to bid-price noncompliance; potential move to the over-the-counter market could reduce liquidity and pressure the share price.

Insights

Delisting risk is material; appeal and reverse split aim to cure.

Cycurion received a Nasdaq delisting determination after not meeting the $1.00 bid price requirement over the allowed period. The company appealed on October 20, 2025, which stays suspension pending a panel hearing typically in 30–45 days. The board approved a 30:1 reverse stock split expected on October 27, 2025, a standard step to address bid-price compliance.

If the appeal fails or compliance isn’t regained, the shares may shift to the over-the-counter market, which the company states is less liquid and could depress trading prices. The filing also notes $1,000,000 in new contracts expected to add $75,000 in monthly recurring revenue, which provides operating support but does not address the listing rule directly.

Key near-term milestones are the effective date of the reverse split on October 27, 2025 and the panel process following the appeal. Actual outcomes will depend on post-split trading levels and the panel’s decision.

Cycurion, Inc. (CYCU) ha comunicato una decisione di delisting da Nasdaq e ha presentato un ricorso. L'azienda ha ricevuto la notifica il 14 ottobre 2025 che il suo titolo comune è soggetto a delisting dal Nasdaq Global Market dopo non aver rispettato la regola del prezzo di offerta di $1,00. Cycurion ha presentato ricorso il 20 ottobre 2025, che sospende qualsiasi sospensione e la presentazione del Form 25-NSE in attesa della decisione di un pannello, con le udienze tipicamente fissate 30–45 giorni dopo la richiesta.

Per correggere la carenza nel prezzo di offerta, il consiglio di amministrazione ha approvato un reverse stock split di 30:1 previsto per l'entrata in vigore il 27 ottobre 2025, a seguito dell'approvazione precedente da parte degli azionisti di un intervallo di divisione inversa. L'azienda ha anche annunciato cinque nuovi contratti per un totale di circa 1 milione di dollari, che ci si aspetta aggiungano 75.000 dollari di entrate ricorrenti mensili. Se il ricorso non avrà esito positivo, le azioni potrebbero passare al mercato over-the-counter, che l'azienda indica come un recinto di negoziazione più limitato e meno liquido e potrebbe esercitare pressioni sul prezzo delle azioni.

Cycurion, Inc. (CYCU) informó de una determinación de exclusión de Nasdaq y presentó una apelación. La compañía recibió aviso el 14 de octubre de 2025 de que su acción ordinaria está sujeta a la exclusión del Nasdaq Global Market tras no haber logrado volver al cumplimiento con la regla de precio de oferta de $1,00. Cycurion presentó una apelación el 20 de octubre de 2025, que suspende cualquier suspensión y la presentación del Form 25-NSE hasta la decisión de un panel, con audiencias típicamente programadas 30–45 días después de la solicitud.

Para abordar la deficiencia del precio de oferta, la junta aprobó un split inverso de 30:1 que se espera entre en vigor el 27 de octubre de 2025, tras la aprobación previa de los accionistas de un rango de división inversa. La empresa también anunció cinco nuevos contratos por un total de aproximadamente $1 millón, que se espera que agreguen $75,000 en ingresos recurrentes mensuales. Si el recurso no tiene éxito, las acciones podrían pasar al mercado de comercio extrabursátil, que la empresa señala como un recinto de negociación más limitado y menos líquido y podría presionar el precio de las acciones.

Cycurion, Inc. (CYCU)는 나스닥 상장 말소 결정에 따른 조치를 발표했고 항소를 제기했다. 회사는 2025년 10월 14일에 보통주가 $1.00의 호가가 기준을 충족하지 못해 나스닥 글로벌 마켓에서의 상장폐지 대상임을 통지받았다. Cycurion은 2025년 10월 20일에 항소를 제기했으며, 이는 패널 결정까지 정지 및 Form 25-NSE 제출을 보류하며, 청문회는 일반적으로 요청 후 30~45일 내에 설정된다.

호가 요건을 해결하기 위해 이사회는 30:1의 주식 분할을 승인했고, 이는 2025년 10월 27일에 효력을 발휘할 예정이며, 역분할 범위에 대한 주주 승인을 받았다. 회사는 또한 약 100만 달러의 다섯 건의 신규 계약를 발표했고, 월 7만5천 달러의 재발생 수익을 추가할 것으로 예상된다. 항소가 성공하지 못하면 주식은 장외시장으로 이동할 수 있으며, 이는 거래 용량이 더 제한적이고 유동성이 낮은 거래 장소로 간주되며 주가에 압력을 가할 수 있다.

Cycurion, Inc. (CYCU) a annoncé une décision de radiation de Nasdaq et a déposé un recours. La société a reçu le 14 octobre 2025 une notification selon laquelle son action ordinaire est sujette à une radiation du Nasdaq Global Market après n'avoir pas retrouvé le respect de la règle de prix d’offre de 1,00 $. Cycurion a déposé un recours le 20 octobre 2025, qui suspend toute suspension et le dépôt du formulaire 25-NSE en attendant la décision d’un panel, les audiences étant généralement prévues 30 à 45 jours après la demande.

Pour remédier à la déficience du prix d’offre, le conseil d’administration a approuvé un fractionnement inverse de 30:1 qui devrait prendre effet le 27 octobre 2025, après l’approbation préalable par les actionnaires d’une plage de fractionnement inverse. La société a également annoncé cinq nouveaux contrats pour un montant total d’environ 1 million de dollars, qui devraient ajouter 75 000 dollars de revenus récurrents mensuels. Si l’appel échoue, les actions pourraient être transférées au marché des valeurs hors cote (over-the-counter), que la société décrit comme un lieu de négociation plus limité et moins liquide et qui pourrait exercer une pression sur le cours.

Cycurion, Inc. (CYCU) meldete eine Nasdaq-Delisting-Bewertung und legte Berufung ein. Das Unternehmen erhielt am 14. Oktober 2025 die Mitteilung, dass seine Stammaktie aufgrund des Nichteinhaltens der $1,00-Bid-Price-Regel vom Nasdaq Global Market delisted wird. Cycurion legte am 20. Oktober 2025 Berufung ein, wodurch jegliche Suspendierung und die Einreichung von Form 25-NSE bis zur Entscheidung eines Panels ausgesetzt werden, mit hearings typischerweise 30–45 Tage nach der Anfrage.

Um die Bid-Price-Defizit zu beheben, hat der Vorstand eine 30:1 reverse stock split genehmigt, der voraussichtlich am 27. Oktober 2025 in Kraft tritt, nach zuvor von den Aktionären genehmigtem Bereich des Reverse-Splits. Das Unternehmen kündigte außerdem fünf neue Verträge im Gesamtwert von ca. 1 Million Dollar an, von denen erwartet wird, dass sie 75.000 Dollar an monatlich wiederkehrenden Einnahmen hinzufügen. Sollte die Berufung scheitern, könnten die Aktien in den OTC-Markt übergehen, den das Unternehmen als einen begrenzteren und weniger liquiden Handelsplatz bezeichnet und der den Aktienkurs unter Druck setzen könnte.

false 0001868419 0001868419 2025-10-14 2025-10-14 0001868419 CYCU:CommonStockParValue0.0001PerShareMember 2025-10-14 2025-10-14 0001868419 CYCU:RedeemableWarrantsEachExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember 2025-10-14 2025-10-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): October 14, 2025

 

CYCURION, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware   001-41214   86-3720717
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

 

1640 Boro Place, Fourth Floor    
McLean, Virginia   22102
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (310) 740-0710

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common stock, par value $0.0001 per share   CYCU   The NASDAQ Stock Market LLC
Redeemable warrants, each exercisable for one share of common stock at an exercise price of $11.50 per share   CYCUW   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On October 14, 2025, Cycurion, Inc. (the “Company”) received a Delisting Determination Letter from the staff of Nasdaq Listing Qualifications (the “Staff”) that it has determined to commence proceedings to delist the common stock, par value $0.0001 per share, of the Company (ticker symbol: CYCU), from the Nasdaq Global Market (the “Nasdaq”).

 

As previously announced in a Current Report filed with the Securities and Exchange Commission (the “SEC”), on April 15, 2025, the Staff notified the Company on April 9, 2025 that, for the prior 30 consecutive business days, the closing bid price of the Company’s common stock had been below the minimum of $1.00 per share required for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The notification letter stated that the Company would be afforded 180 calendar days, or until October 6, 2025, to regain compliance.

 

The Company has not regained compliance with the Bid Price Rule, and the listed security is now subject to delisting from The Nasdaq Global Market. Unless the Company requests an appeal of the Staff’s determination by October 21, 2025, trading of the Company’s shares of common stock will be scheduled for delisting at the opening of business on October 23, 2025, and Nasdaq intends to file a Form 25-NSE with the SEC, removing the Company’s shares of common stock from listing and registration on The Nasdaq Stock Market.

 

On October 20, 2025, the Company submitted its request to the Nasdaq Global Market to appeal the Staff’s determination to a Hearings Panel (the “Panel”) pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. A hearing request will stay the suspension of the Company’s securities and the filing of the Form 25-NSE pending the Panel’s decision. The Company has been informed by the Staff that Panel hearings are typically scheduled to occur approximately 30-45 days after the date of the hearing request

 

On October 10, 2025, the Company’s board of directors determined to effect a 30:1 reverse stock split to regain compliance with the Bid Price Rule, which is expected to take effect on October 27, 2025. As previously announced, holders of a majority of the Company’s issued and outstanding common stock, including certain holders of shares of preferred stock, which shares vote together with the shares of common stock, approved a reverse stock split proposal at a reverse stock split ratio ranging between and including 3:1 to 75:1 and in the aggregate not more than 250:1, inclusive, by written consent as set forth in the Company’s definitive Information Statement filed with the U.S. Securities and Exchange Commission on September 9, 2025. The reverse stock split proposal became effective on September 29, 2025.

 

If the Company does not regain compliance with Nasdaq’s continued listing standards or its appeal is unsuccessful, it is expected that its shares of common stock will be delisted from Nasdaq, in which case, the Company may apply to list its shares of common stock on the over-the-counter market. The over-the-counter market is a significantly more limited market than Nasdaq, and quotation on the over-the-counter market likely results in a less liquid market for existing and potential stockholders of the Company to trade its shares of common stock and could depress the trading price of the shares of common stock. The Company can provide no assurance that its shares of common stock will continue to trade on this market or the over-the-counter market, that broker-dealers will continue to provide public quotes of the shares of common stock, or that the trading volume of the shares of common stock will be sufficient to provide for an efficient trading market.

 

Item 8.01 Other Events.

 

On October 14, 2025, the Company announced that it has engaged counsel to pursue its legal remedies against individuals or groups who appear to have disseminated false and misleading information, defamed the Company and libeled its executives, which actions seem designed to undermine investor confidence and harm the Company’s reputation. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

On October 16, 2025, the Company announced the successful closure of five new contracts, totaling approximately $1 million in value, which are expected to generate an additional $75,000 in monthly recurring revenue. A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

 

 

 

 

On October 20, 2025, the Company announced that it received a Delisting Determination Letter from the Staff that it has determined to commence proceedings to delist the Company’s shares of common stock from The Nasdaq Global Market, as discussed in more detail in Item 3.01 of this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.3 to this Current Report on Form 8-K.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Current Report contains forward-looking statements within the meaning of U.S. federal securities laws. Such forward-looking statements include, but are not limited to, statements regarding the Company’s appeal of the Staff’s determination, the potential delisting of the Company’s shares of common stock from The Nasdaq Global Market, the trading of the Company’s shares of common stock on the over-the-counter market, the projected operation and financial performance of the Company, and the Company’s expectations, hopes, beliefs, intentions, plans, prospects or strategies regarding the future revenue and the business plans of the Company’s management team. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this Current Report are based on certain assumptions and analyses made by the management of the Company considering their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on the Company as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including whether the Company will be able to regain compliance with the continued listing standards of the Nasdaq or comply with the initial listing standards of another national securities exchange, the ability of the Company to service or otherwise pay its debt obligations, including to holders of the Company’s convertible notes, the mix of services utilized by the Company’s customers and such customers’ needs for these services, market acceptance of new service offerings, the ability of the Company to expand what it does for existing customers as well as to add new customers, that the Company will have sufficient capital to operate as anticipated, and the demand for the Company’s products, and economic activity in general. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as may be required under applicable securities laws.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits:

 

Exhibit No.   Description
99.1   Press release dated October 14, 2025
99.2   Press release dated October 16, 2025
99.3   Press release dated October 20, 2025
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CYCURION, INC.
     
Date: October 20, 2025 By: /s/ L. Kevin Kelly
  Name: L. Kevin Kelly
  Title: Chief Executive Officer

 

 

 

 

FAQ

What did Cycurion (CYCU) announce regarding its Nasdaq listing?

The company received a delisting determination on October 14, 2025 for not meeting the $1.00 bid-price rule and filed an appeal on October 20, 2025, which stays suspension pending a panel decision.

What steps is CYCU taking to regain bid-price compliance?

Its board approved a 30:1 reverse stock split expected to take effect on October 27, 2025, following prior stockholder approval of a reverse-split range.

When could the Nasdaq hearing occur for CYCU’s appeal?

Panel hearings are typically scheduled approximately 30–45 days after the hearing request, which was submitted on October 20, 2025.

What happens if Cycurion remains noncompliant with Nasdaq rules?

Its common stock may be delisted and could transition to the over-the-counter market, which is described as less liquid and potentially price-depressive.

Did Cycurion report any new business wins?

Yes. It announced five new contracts totaling approximately $1 million, expected to generate an additional $75,000 in monthly recurring revenue.

What Nasdaq rule did CYCU fail to meet?

The minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2).
Cycurion Inc.

NASDAQ:CYCU

CYCU Rankings

CYCU Latest News

CYCU Latest SEC Filings

CYCU Stock Data

19.88M
58.96M
27.8%
4.42%
8.89%
Information Technology Services
Services-computer Programming Services
Link
United States
MCLEAN